Related Experiment Video

Updated: Mar 3, 2026

Transcutaneous Microcirculatory Imaging in Preterm Neonates
06:27

Transcutaneous Microcirculatory Imaging in Preterm Neonates

Published on: December 31, 2015

8.6K

Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study

Yi Ji1, Siyuan Chen2, Bo Xiang3

  • 1Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, 610041, China. jijiyuanyuan@163.com.

Scientific Reports
|May 6, 2017
PubMed

Insights

Propranolol is safe for treating infantile hemangiomas (IHs) in neonates. Close monitoring is recommended for high-risk infants, but side effects were generally mild and transient.

Area of Science:

  • Neonatal Medicine
  • Pediatric Dermatology
  • Pharmacology

Background:

  • Infantile hemangiomas (IHs) are common vascular tumors in neonates.
  • Propranolol is effective for IH treatment, but safety data in neonates is limited.
  • Neonates may have unique physiological responses to medications.

Purpose of the Study:

  • To evaluate the safety and tolerance of propranolol in neonates with severe IH.
  • To assess hemodynamic and glycemic effects of propranolol in this population.
  • To identify potential adverse events associated with neonatal propranolol use.

Main Methods:

  • Prospective study of 51 neonates (<30 days old) with severe IH.
  • In-hospital monitoring during initial propranolol treatment and dose adjustments.
  • Evaluation of heart rate, blood pressure, blood glucose, and side effects.

Main Results:

  • Significant decreases in mean heart rate and systolic blood pressure observed.
  • No significant changes in diastolic blood pressure or blood glucose levels.
  • Transient, asymptomatic bradycardia and hypotension occurred in some patients; bronchial hyperreactivity in two.

Conclusions:

  • Propranolol is safe and well-tolerated in carefully selected neonates with severe IH.
  • Close monitoring is advised, especially for high-risk neonates.
  • Further research on long-term outcomes is warranted.

More Related Videos

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography09:31

Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography

Published on: January 27, 2023

1.7K
A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn11:27

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

Published on: April 7, 2023

7.6K

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of &#946;-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
457
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
411
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
293
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
388